Kyorin Holdings Inc
TSE:4569
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Paion AG
XETRA:PA8
|
DE |
|
Biogen Inc
NASDAQ:BIIB
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (14.4), the stock would be worth ¥3 438.47 (118% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.6 | ¥1 580 |
0%
|
| 3-Year Average | 14.4 | ¥3 438.47 |
+118%
|
| 5-Year Average | 15.8 | ¥3 776.56 |
+139%
|
| Industry Average | 17.5 | ¥4 165.85 |
+164%
|
| Country Average | 13.6 | ¥3 251.85 |
+106%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Kyorin Holdings Inc
TSE:4569
|
90.8B JPY | 6.6 | 8.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 29.2 | 40.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 21.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 21.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 11.6 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.9 | 16.7 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 9.8 |
| Median | 13.6 |
| 70th Percentile | 18.1 |
| Max | 414 821 439 |
Other Multiples
Kyorin Holdings Inc
Glance View
KYORIN Holdings, Inc. engages in the development, manufacture and sale of pharmaceutical products through its subsidiaries. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 2,243 full-time employees. The company went IPO on 2006-03-10. The firm operates through two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sales of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, as well as the research of new drugs and candidate compounds. The company also engages in the purchase and sales of medical promotion tools and packaging materials. The Healthcare segment is engaged in the manufacturing, sales and purchase of environmental sanitation products, general purpose medicines and skin care products.
